Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 372


CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.

Kim HA, Ko HM, Ju HW, Kim KJ, Roh SG, Lee HK, Im SY.

Cancer Lett. 2009 Feb 8;274(1):160-4. doi: 10.1016/j.canlet.2008.09.014. Epub 2008 Oct 25.


Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.

de Jong S, Chikh G, Sekirov L, Raney S, Semple S, Klimuk S, Yuan N, Hope M, Cullis P, Tam Y.

Cancer Immunol Immunother. 2007 Aug;56(8):1251-64. Epub 2007 Jan 23.


Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.

Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdörfer B, Krug A, Rothenfusser S, Endres S, Hartmann G.

J Immunol. 2002 Oct 1;169(7):3892-9.


Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo.

Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, Lehr HA, Krieg AM, Hartmann G, Endres S.

J Immunol. 2000 Dec 1;165(11):6278-86.


Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.

Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E, Rothenfusser S, Endres S, Hartmann G.

Eur J Immunol. 2002 Nov;32(11):3235-45.


Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.

Daftarian P, Song GY, Ali S, Faynsod M, Longmate J, Diamond DJ, Ellenhorn JD.

Cancer Res. 2004 Aug 1;64(15):5407-14.


Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.

Ren T, Wen ZK, Liu ZM, Qian C, Liang YJ, Jin ML, Cai YY, Xu L.

Cancer Invest. 2008 Jun;26(5):448-55. doi: 10.1080/07357900701681608.


Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model.

Cho HC, Kim BH, Kim K, Park JY, Chang JH, Kim SK.

Int Immunopharmacol. 2008 Oct;8(10):1401-7. doi: 10.1016/j.intimp.2008.05.010. Epub 2008 Jun 18.


Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.

De Cesare M, Calcaterra C, Pratesi G, Gatti L, Zunino F, Mènard S, Balsari A.

Clin Cancer Res. 2008 Sep 1;14(17):5512-8. doi: 10.1158/1078-0432.CCR-08-0445.


Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells.

Chamoto K, Takeshima T, Wakita D, Ohkuri T, Ashino S, Omatsu T, Shirato H, Kitamura H, Togashi Y, Nishimura T.

Cancer Sci. 2009 May;100(5):934-9. doi: 10.1111/j.1349-7006.2009.01114.x. Epub 2009 Feb 24.


Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.

Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ.

J Immunol. 2001 Nov 1;167(9):4878-86.


CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction.

Garbi N, Arnold B, Gordon S, Hämmerling GJ, Ganss R.

J Immunol. 2004 May 15;172(10):5861-9.


Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis.

Xiong Z, Gharagozlou S, Vengco I, Chen W, Ohlfest JR.

Clin Cancer Res. 2008 Sep 1;14(17):5484-93. doi: 10.1158/1078-0432.CCR-07-4139.


Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.

Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S.

Int J Oncol. 2004 Apr;24(4):901-8.


[Therapeutic and immunological effects of microwave ablation combined with CpG ODN on transplanted colon carcinoma in mice].

Zou N, Li XF, Ding WM, Lai QH, Zhang JR.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 May;30(5):984-8. Chinese.


Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy.

Kigasawa K, Kajimoto K, Nakamura T, Hama S, Kanamura K, Harashima H, Kogure K.

J Control Release. 2011 Mar 30;150(3):256-65. doi: 10.1016/j.jconrel.2011.01.018. Epub 2011 Jan 21.


Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.

Hamzah J, Altin JG, Herringson T, Parish CR, Hämmerling GJ, O'Donoghue H, Ganss R.

J Immunol. 2009 Jul 15;183(2):1091-8. doi: 10.4049/jimmunol.0900736. Epub 2009 Jun 26.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk